Combination treatment for advanced MSI-H cancers
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug (LM-108) combined with an existing immunotherapy (toripalimab) for people with advanced cancers that have a specific genetic feature (MSI-H or dMMR). The goal is to see if this combination can help when previous immunotherapy hasn't worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced cancer that has spread or cannot be removed with surgery.
- Your tumor has a specific marker called MSI-H or dMMR, which can be checked with a test.
- You must have already tried a type of immunotherapy (like Keytruda or Opdivo) and it didn't help enough or stopped working.
- You are 18 or older and able to carry out daily activities with mild effort.
- You need to have a tumor sample available for testing (either from a previous biopsy or you are willing to have a new biopsy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called LM-168, either alone or combined with another cancer treatment, for people with advanced solid tumors that have not responded to standard therapies. The goal is to see if it can shrink tumors or slow their growth.
This study tests a combination of two investigational drugs (Simmitinib and SG001) in people with advanced solid tumors that have not responded to standard treatment. The goal is to see if this combination can shrink tumors or slow their growth, and to find the best dose for further studies.
This trial tests an oral medication called MOMA-341 in people with advanced solid tumors that have high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR). It aims to see if the drug can help when prior immunotherapy hasn't worked or isn't available.
This trial tests a new combination of two medications (IPG7236 and Toripalimab) for people with advanced solid tumors that have not responded to standard therapies. The goal is to see if the combination is safe and effective.
This trial tests APG-115 together with a PD-1 immune therapy in people with advanced liposarcoma or other advanced solid tumors. It may help by blocking tumor growth through a mix of direct tumor targeting and immune system activation.
This study tests a new drug (DS5361b) for people with advanced solid tumors that have high genetic instability (TMB-H or MSI-H). It aims to see if the drug can shrink tumors or slow their growth.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.